BioPharma Drive: Drug Pricing
SEPTEMBER 8, 2024
Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.
Drugs.com
SEPTEMBER 8, 2024
SUNDAY, Sept. 8, 2024 -- Getting older tends to go hand in hand with failing vision, but eye experts say there are things you can do to preserve your sight as you age.The risk of age-related macular degeneration (AMD) and diabetic retinopathy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
SEPTEMBER 8, 2024
In this Column, Spencer Greenberg and Amber Dawn Ace explain how charts can inadvertently manipulate reality. In 1994, the U.S. Congress passed the largest crime bill in U.S. history, called the Violent Crime Control and Law Enforcement Act. The bill allocated billions of dollars to build more prisons and hire 100,000 new police officers, among other things.
New Drug Approvals
SEPTEMBER 8, 2024
Palopegteriparatide Yorvipath , FDA 2024, 8/9/2024, To treat hypoparathyroidism G2N64C3385 2222514-07-8 Palopegteriparatide UNII-G2N64C3385 ACP-014 Mpeg 40000-teriparatide Palopegteriparatide [INN] Transcon parathyroid hormone (1-34) Transcon pth (1-34) Palopegteriparatide [USAN] TransCon PTH WHO 11060 Palopegteriparatide Palopegteriparatide is a human parathyroid hormone analogue corresponding to amino acid residues 1 – 34 of human parathyroid hormone, to which a methoxy polyethylene glycol (mo
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Perficient: Drug Development
SEPTEMBER 8, 2024
UX in Universal Design Series: Key Principles of Usability for Physical Disabilities in Health Systems In healthcare, accessibility and usability are essential to ensuring that all patients, including those with physical disabilities, receive equal care. For individuals with physical disabilities, navigating healthcare facilities and interacting with medical devices can pose significant challenges.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Perficient: Drug Development
SEPTEMBER 8, 2024
Designing health systems that are inclusive for individuals with physical disabilities is crucial for ensuring equal access to healthcare. Despite progress, many healthcare environments still present significant challenges for these patients. In this installment of the UX in Universal Design Series, we will explore the challenges faced when designing for physical disabilities and highlight the opportunities that exist to make health systems more accessible, functional, and inclusive.
New Drug Approvals
SEPTEMBER 8, 2024
Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47 fda approved 8/14/2024, To treat primary biliary cholangitis (PBC), Livdelzi Ingredient UNII CAS InChI Key Seladelpar lysine N1429130KR 928821-40-3 WTKSWPYGZDCUNQ-JZXFCXSPSA-N (+)-MBX-8025 MBX 8025 MBX-8025 MBX8025 RWJ-800025 ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVAT
Expert insights. Personalized for you.
333 
Let's personalize your content